GSK Investigational Site

Goch, North Rhine-Westphalia 47574

0 studies enrolling now · 21 studies all time

What they study most

Arthritis, Rheumatoid, Asthma, Atherosclerosis, Diabetes Mellitus, Type 2, Herpes Zoster, Herpes Zoster Vaccine, Infections, Rotavirus, Influenza, Pulmonary Disease, Chronic Obstructive, Respiratory Syncytial Virus Infections, Rotavirus Vaccines, Skin Infections, Bacterial

Studies at this site

• A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults — Running, not enrolling
• Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older — Completed
• A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women — Completed
• Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies. — Completed
• Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older — Completed
• Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks — Completed
• A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022 — Completed
• Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older — Completed
• Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older — Completed
• A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children — Completed
• Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older — Completed
• Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks — Completed
• Asthma Exacerbation Study — Completed
• Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide — Completed
• Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD — Completed
• The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial — Completed
• Thiazolidinedione Intervention With Vitamin D Evaluation — Stopped early
• COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis — Completed
• Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections. — Completed
• SB-480848 In Subjects With Coronary Heart Disease — Completed